�.4 N�

�-�Jii�1�iiE;iA lucutlv#{149} Diniictoz

R&th.�d� . in � ii

S. � #{176}� �#{176}#{176}-“114d..s O�4.s ii � 14.1. 1 Piicuii ii ii... .4 Turn Auuuw .4 S..4.. M.np.. ii 04.,

966

4,;, St.t.msnt of Ownership.Management and

= Circulation(A.q.4�d by 39 U.S.C. 3686)

IA. T�. �E P,EI�c.s#{246}... I is. �isuc*no.. ,#.o.

DRUG METABOLISM � DISPOSITIOS [� � I �1� �jj �I. F..q....y �l � M. N..41......

&L�)th1v 6

2. D.s. .4 F�

6 � 10192

S. A�u� $.�w�pth�P$.s

$80.00

4. C.s. Mi� Md,... .1 knsw#{248}Oflics .� Pg�icss*, �... Ck�. � � �W+4 C�#{224}J�

429 1. Pr�ton St.z�t, Saltiaor#{149}, MaZI�1aM 21202-3993

L C..�i.s. � Ad*... si ths $.�ns,s Id � �.. OI� .1 b. P�hi... �

429 1. Prstao Stz.1, Mltiaor, Naz�1and 21202-3993

S Fd N.rn.. �M � M.d� Ad*sss �4 � � �d M.�0m. #{163}d.s..(ThN � MUST80Tk �I

p.-. � �jc� �wlllia_ � WLLkin*, 429 1. Preston Stz1, #{163}i1U�r#{149},Nmrjjland 21202-3993

,4�. � _d � �DC. Vincent C. Z�tmon1 , D.pI. of Pharaacology, Un.lv.raity of NlchAgan Pad.lcal School,

lox. Ann *rboc, SI 49109

,. � � � i, � �, � � .� �. � � - �,p.,,,�� � V.� � � 4’ �. � .f�. � b� $.�.dby.� � � � - .,l. 4,..* � k �.. � i � .. � �__4.�,u_.b,_, S,.�w9,�w4) ________________________________

��‘#{176}V iq� rm��sooiocu c/o Ka�j Ctch.r

xo,uI�CiVZ#{227}hI .

,,�N�. c_ M� Ad*...-

S. P.. � by � O�g�WUIl�. A..U.�fliii T� Mid * $�Th� � � � �,I4 � #{149}I� � ... W..

II) �2)c� Hu� N.e Ch.� Owl., N.� chu�d D..mqp,.#{176}#{176}�,.%3 � P..c.� U M...t

j�. � 4NI2 g4� � I.. � � �s � �.d

W.�#d. � .� � ,,� 4.�, � �.

,o. � �d � ii �

�, � - ..w,- �A,�.. N�. CS... LcD. Isc� D..p,.c.d.,.*2 M..wI.�

Ao� N. C.#{216}.. .4 S..1. �P�e4..d NM�� $� F�.#{149} Diii

A. TuiiDi.Ciphii�ii�Dis� 1905 1654

S. Piid sid* Diuuii.d CNc.iius, � �LWm. sd.. � � iid c*fliii. sS..ss .ii.uw. .� .ii�ii .4..

150 82

3. N.j s4..i_..�w �

990 964

C. 744 P44 ..dii, Di�iisisd C�c4ii.44.. 414.1 .� a�Z�

1140 1046

0. Vii. Dii4..#ii. by Mu. Cw* Ouii M.smshi_i. C...isiiy. � Dii. Fvss C.ss

95 98

I. Tii4D.44..4�8..4C�4D#{248} 1225 1144

9.C�NiiD.4*.�I. oo� .�., i.ii .,... �.t � .8.. �

sac szo

z. a.....h� N..#{149} Ai�. �S IONS

0. TOTAl. �.m 46. Fl iidI-4ii4h.spm. � 4... ii Al 1805 1654

II. I #{176}.#{176}‘.‘�-� TN. .4 #{163}4.4..P.iiu4�. � � .,I c.nWy thu 0. st�nss ...d. by

In. ibov#{149} s covi�cl iiid com�l, � �1.d�64c_. 4�2..gm_It�.) Piibllsher

PS Pu.. 3626. i� 101 0.. Miii... ii uw,w) 8Pa14 SuDi, aalh#{149}d b� otb.r ana

967

AUTHOR INDEX

Abbott, Frank S., 45 1, 840

Ackermann, Bradley L., 89Adusumalli, V. E., 530Ag#{252}ndez,J. A. 0., 343Ahlner, Johan, 553Akhtar, M. Humayoun, 356Alderweireldt, F. C., 507Almirez, Ramona, 19Al-Tayib, Yousuf, 889

Alvares, Alvito P., 19

Andersson, K.-E., 148

Aoki, Kimiko, 52Aoki, Syouichi, 541Aoyama, Toshifumi, 566

Arison, Byron H., 869Asbury, Karen J., 616

Axelsson, Krister L., 553

Balani, Suresh K., 869

Baldeck, Jean-Pierre, 603, 802Ball, Simon E., 56

Ballantyne, Bryan, 6Balzarini, Jan, 747Barnes, Stephen, 1 13Barzago, Maria Monica, 826Bates, Theodore R., 572Batt, Anne-Marie, 407Beedham, Christine, 889Beers, Scott A., 47

B#{233}langer, Pierre M., 762Bell, Randy, 328Benet, Leslie Z., 547

Benincosa, Lisa J., 461Benitez, J., 343Benoit, Etienne, 877

Berger, Yves, 316Bertler, Ake, 553Beskitt, Joyce L., 6Bickers, David R., 620Biglino, Giuseppe, 742Blaschke, Terrence F., 379Boal, Jila H., 337Bock,K.W., 137

Boelsterli, Urs A., 96Boger, Robert S., 821Bonati, Maurizio, 826

Bornheim, Lester M., 241Bortolotti, Angela, 826

Bourrie, Martine, 316Bouska, Jennifer, 328Boyer, C. Scott, 863Boyle, Kathleen E., 695Breimer, Douwe D., 502Brendel, Klaus, 802Brewer, C. Fred, 902Britto, Margaret R., 446

Brouwer, Kim L. R., 496, 810

Brown, Nita S., 936Brown, Thomas J., 849Bryan, George T., 559Bundgaard, Hans, 172

Burgio, D., 302Burka, L. T., 643Byrd, Gary D., 192

Cai, Yuli, 432

Cano, Jean-Paul, 316Cantu, Amador R., 360Caputo, Otto, 742Carlin,J.R., 148Carter, George, 328Castonguay, Andre, 510Catalin, Jacques, 316, 578Catlow,J., 102Celardo, Antonio, 826

Cepa, Steven, 328Ceruti, Maurizio, 742Chadwick, Marjory, 198, 436Chakravarty, Prasun K., 281Chandrasurin, Pisal, 679, 920, 928Chang, David, 954

Chang, Jim, 23Chang, Kuo-Mei, 192

Chang, Wen-Chang, 719Chang, Young H., 337

Chen, 1.-Wu, 390, 473, 608Cheng, Haiyung, 596Cheriathundam, Elizabeth, 19Chien, Du-Shieng, 21 1

Chiu, Shuet-Hing Lee, 281Chow, Hsiao-Hui, 288, 432Christians, Uwe, 186, 753Christofalo, P., 148

Chui, Y. C., 840, 941Clarke, J. B., 625

Coffman, B., 896Connors, Suzanne, 802Cook, C. Edgar, 856

Coon, Minor J., 108, 792Cooper, Allen D., 379Corada, Monica, 826

Corcoran, George B., 402Corcos, Laurent, 797Cornpropst, J. David, 849

Coutant, John E., 89Covington, Wendy P., 936Cresteil, Thierry, 877Crysler, C. S., 396CuIp, Hilman W., 849

Damani, L. A., 256

Damani, Lyaquat A., 736Damani, Lyaquatali A., 64Daniels, William D., 849Darbyshire, John F., 566Davis, Carole J., 792Davis, Charles B., 695Davis, Patrick J.,38, 882

Deal, Donna L., 679, 920, 928

deBethizy, J. Don, 192De Clercq, Erik, 747

De Cock Buning, T. J., 507Delatour, Paul, 877

Deleon, Jesus H., 156DeLisa, Anne, 706Deloria, Laurel B., 142Deluna, Florencia A., 428, 608Dewey, R. H., 479Diasio, Robert B., I 13

Diaz, Rolando G., 156

Digenis, G. A., 124

Ding, Xinxin, 792

D’Mello, Anil P., 572Dobbin, P. 5., 256Dommisse, R., 507Donehower, Ross C., 706Dorley, Joan M., 390Doss,GeorgeA., 281

Dueker, Stephen R., 275Duescher, Renee J., 658Duffel, Michael W., 339Duggan, Daniel E., 473

Eddy, A. C., 832Egestad, Bomje, 470

Ehlhardt, William J., 958Elfarra, Adnan A., 658

Ellis, B. L., 256Elsea, Sarah H., 23

Epemolu, Ola R., 736Epemolu, R. 0., 256Eriksson, L.-O., 148

Fabre, Gerard, 316

Farooqui, Mohammed Y. H., 156

Fekete, Tibor, 234Feng, PaulC. C., 616Ferrari, Luc, 407Findlay, John W. A., 679, 920, 928Fischer, Volker, 603, 802

Fisher, Robyn L., 802Fong, Kei-Lai, 396

Fong, Kei-Lai L., 695Franklin, Michael R., 726

Frantz, Stephen W., 6Frydman, Armand, 490

Fujita, Shoichi, 367Fukao, Katashi, 773Fukui, Hiroshi, 585Funae, Y., 79Funae, Yoshihiko, 367

Gallo, James M., 396

Garland, William A., 954Gascon, Marie-Paule, 592

Gatto, Gregory J., 281Ghanayem, B. I., 643

Gibson, G. Gordon, 779Gielen, Jacques E., 407Gillette, James R., 566Glauser, Todd A., 247Gleason, J. G., 479G#{246}ldlin,Christian, 96Goldman, Mark E., 869Gonzalez, Frank J., 566Gooley, Paul R., 665Gordon, W. Perry, 596Granneman, G. Richard, 821

Grant, David F., 779Grau,GeorgesE., 592

Grech-B#{233}banger, Odette, 762Green, M. D., 896

Greene, Jackie M., 192Gregoire, S. L., 148

Gregus, Zolt#{226}n,234, 374Grochow, Louise B., 706Groen, Kees, 502

Grosa, Giorgio, 742Grosse, Christine M., 6Guaitani, Amalia, 826Guengerich, F. Peter, 753Guenthner, Thomas M., 440Gupta, Samir K., 821Guzelian, Philip S., 31

Haggard, K., 948

Hall, Stephen D., 322Hamilton, Marta, 849

Hansen, Kristian T., 172Hanzlik, Robert P., 688Haqqi, Tariq M., 620Harker, W. Graydon, 632

Hasegawa, Takaaki, 653Hashizaki, Man, 816

Hawi,A.A., 124

He, Yan-Ling, 541

Henderson, Laura, 954Hermans, J. J. R., 268Hern#{227}ndez, J. Sergio, 413Hezari, Mehri, 882Hichens, Martin, 608Hider, R. C., 256

Hider, Robert C., 736Higaki, Kazutaka, 350

Hill, Judith M., 856

Hiraoka, K., 226Ho, Chorng-Kei, 337Ho, Dah H., 936Hoener, Betty-Ann, 547Hoffman, Jacob M., 869Hofstra, Angela H., 205Hoglund, P., 148Hollenberg, Norman K., 821Hopkins, William E., 616Hori, Ryohei, 541

Hsieh, Yin-Yi, 719Huang, Jin-Ding, 719

Hunt, Christine, 31Hurowitz, Lisa, 706

Hurst, Gail H., 89Hwang. KinKai, 23

Ibrahim, Safaa S.,47

Ichimura, Fujio, 485, 730Imaoka, S., 79

Imaoka, Susumu, 367Inaba,T., 1,465Ingelman-Sundberg, M., 137

Inui, Ken-Ichi, 541Ishizaki, Junko, 485

Isikawa, Akio, 773

Iwasaki, Youji, 773

Jarman,M., 941

Jaruratanasirikul, Sutep, 379

Jeffcoat, A. Robert, 856Johnson, Randall, 706

Jorquera, Rossana, 510Juchau, Mont R., 218

968 AUTHOR INDEX

Kabow, W., 1, 465Kamimura, Hidetake, 309Kang, Y. James, 714Karisson, Karl-Enk, 262Karnes, H. Thomas, 31Kato, Katsuyoshi, 653

Kato, M., 226Kato, Y., 161Kauffman, Laura R., 869Kaufmann, Scott H., 706

Kawahara, Seiichi, 179Kenna, J. G., 625Kerkvliet, Nancy I., 467Kerremans, Adrian L., 247Khan, Islam U., 620Khokhar, Abdul R., 673

Kido, Yuichiro, 673Kim,HyoJ., 374

Kimura, R., 161King, Joyce D., 869King, Roberta S., 339

Kiss, A. D., 948Kitamura, S., 226

Kitteringham, N. R., 625Kbaassen, Curtis D., 234, 374

Knadler, Mary Pat, 89Kokkonen, P. S., 941

Komura, Hiroshi, 585Koop, Dennis R., 775

Korzekwa, Kenneth R., 566Kraft, Joan Creech, 218Krakoff, Irwin H., 936Kremers, Pierre, 407

Krishna, D. R., 909Kruse,C., 186

Kucharczyk, N., 84, 525, 530, 536Kuo, Be-Sheng, 23Kuritani, Jun, 936Kuroiwa, Yukio, 52Kusmik, William F., 23

Lacarelle, Bruno, 316, 578Ladona, Margarita, 56

Laethem, Carmen L., 775Labande, Marcel, 762Lalka, David, 288

Lam#{233},Michael W., 275Landmesser, Nelson G., 596

Lanens, D., 507Lanzotti, Adriana, 96Larsen, Douglas L., 596Lasker, Jerome M., 241Le Cotonnec, Jean-Yves, 592Levine, Walter G., 902Li,AbbyA., 616Lim, Heng-Keang, 632Li-Muller, S. M. Angela, 205Lin, Jiunn H., 390, 428, 473, 608Linck,A., 186Liu, Mei-Jen, 810

Liu, Tiepu, 1 13Ludeman, Susan, 706Ludeman, Susan M., 337Luengo, A., 343

Lugtenburg, J., 507Luo, Gang, 440Luther, Robert R., 821Lynn, R. K., 479

Maca, B., 330Machinist, Joseph, 328

MacKenzie, Neil E., 665Madhu, Cherukury, 374Madyastha, K. Madhava, 295Magdalou, Jacques, 779Mahadevan, S., 356Mahon, W. A., 465

Mannering, Gilbert J., 142Markham, Peter M., 436Marre, Fran#{231}oise,316Martinet, Michel R., 490Masubuchi, Yasuhiro, 367Matsunaga, T., 79Matsushita, Ryo, 730Maurer, Gerard, 56, 802Mayersohn, Michael, 432McCabe, Francis L., 706McCarthy, M. E., 479McComish, Madeline F., 198McLean, C., 625

McNamara, P. J., 302McNulty, Michael J., 679, 928

Mehta, Mehub, 396Meier, G. P., 832Menon,K.M.J., 108Messing, Edward M., 559Miller, Randall R., 281Minick, Douglas J., 920

Mizutani, Tamio, 816Modi, Raken B., 339Mongan, Amy L., 436Moody, David E., 726, 779

Morn, Dexter, 275Morino, Akira, 585

Morris, M., 84Morris, Marilyn E., 461Mukhtar, Hasan, 620Mulder, G. J., 507Muller, H. J., 507Muraoka, Isao, 653Mutlib, A. E., 45 1, 840

Nabeshima, Toshitaka, 653

Nadai, Masayuki, 653Naesens, Lieve, 747

Nagano, Taizo, 485Nakanishi, Takeaki, 730

Nakano, Masayuki, 179, 350Nakashima, Emi, 485, 730Narimatsu, S., 79Nanmatsu, Shizuo, 367NcNulty, Michael J., 920Nellans, Hugh N., 328

Nelson, Fred R., 679Neumann, Catherine M., 467Newman, Robert A., 936

Newton, J. F., 479

Nicoll-Griffith, D., 383Niessen, W. M. A., 941

Nilsson, Ingemar, 262Noe, Dennis A., 706

Nomeir, Amin A., 198Nomeir, Ann A., 436Norlander, Bj#{228}rn,553

O’Brien, Julie A., 869

Oertbe, Maja, 96

Oesch, Franz, 614Ogata, Hiroyasu, 309

Ohishi, N., 161Ohtsuka, Masaaki, 773

Okumura, Kazuo, 541Olson, Michael J., 518

Otton, S. V., 1

Page, Tanya L., 928Paradysz, Robert T., 695Pare, J. R. Jocelyn, 762

Park, B. K., 625Patanella, James E., 912Patzelov#{226},V., 330Pazdur, Richard, 936Peegel, Helle, 108Peng, Hwei-Ming, 792

Perchonock, C. D., 479Perez-Reyes, Mario, 856

Pernecky, Steven J., 792Petersen, Dennis R., 863Piguet, Pierre-Francois, 592Piguet, Veronique, 490Pink, Jay C., 559Pitzenberger, Steven M., 390, 869

Placidi, Michel, 578Plakas, Steven M., 70Pollack, Gary M., 810Pomerantz, Steven C., 632

Poole, James C., 23Poon,G.K.,941Porchet, Herv#{233}C., 592

PospIiil, J., 330Prueksaritanont, Thomayant, 547Pugh, Dorothy E., 856

Qato, Mazen K., 440Qian, Mingxin, 396

Raber, Martin N., 936Radeke, H. H., 186

Ragner, Jonathan A., 596Rahmani, Roger, 316, 578

Raj, C. Paul, 295Rajaonarison, Jean Francois, 578

Ramjit, Ham G., 869Ramjit, Harry G., 390Rao, M. Sambasiva, 779Rasori,R., 383

Raucy, Judy L., 241Ray, James E., 958Reahal, Satinderpal, 423Reiners, John J., Jr., 360

Remmel, Rory P., 47Rettie, A. E., 832Reznikoff, Catherine A., 559Riviere, Jean-Louis, 877Rodriguez, Rosita J., 962Rooney, Clarence S., 869

Rosegay, Avery, 281Rowinsky, Eric K., 706

Rowlands, M. G., 941Rozman, Peter, 374

Ruenitz, Peter C., 770

Ruzicka, Jan A., 770

Sadeque, A. J. M., 832Sadler, Brian M., 856

Sakai,T., 127

Salazar, Daniel E., 402Sanchez, I. M., 643

Sandri, Rhonda B., 21 1Sarkar, Mohamadi A., 31

Sasaki, Hideki, 585Sato,M., 161

Sattler, M., 186Sattler, Martin, 753

Savina, Paul M., 496

Schaeffer, William H., 130

Schentag, Jerome J., 402Schiebel, H. M., 186SchOller, Alfred, 360Schrenk, D., 137Schuller, Hildegard M., 510

Segall, H. J., 275

Sellers, E. M., 1

Sewing, Karl-Fr., 186, 753Sharer, Jane E., 658Shima, Tomoko, 541Shipley, Lisa A., 849

Shockcor, John, 679, 920Shoeman, Janice A., 142

Siddik, Zahid H., 673Siest, Gerard, 407Silveira, Denise M., 198, 436Singh, S., 256

Singh, Surinder, 736Sipes, I. Glenn, 665

Sjaberg, Per, 470Sladek, N. E., 134Smith, Brian R., 706Smith, John A., 889

Smith, Philip C., 962Smith, Soozy J., 566

Sofia, R. D., 84, 525, 530, 536Sokoluk, Bridget, 120Song, Wei Q., 962

Soong, Seng-Jaw, 113Spanoghe, M., 507

Steams, Ralph A., 281Stehly, Guy R., 70

Steppan, Linda B., 467Straub, K. M., 479

Styczynski, P. B., 896Subrook, Stephen E., Jr., 518

Sugiyama, Katsumi, 566Suzuki, Tokuji, 367Svensson, Craig K., 74Swaffar, Diane S., 632Swagler, Anne R., 396Swaminathan, Santhanam, 559Swanson, S. P., 102Sweeny, David J., 328

Sweet, Edward M., 337

Tajima, Kazuo, 816Takahara, Hiromi, 309Takaori,M., 127Takayasu, Tatsunori, 485Takeda, Masami, 730

Tallant, Marilyn J., 6Tanaka, Einosuke, 773

Tang-Liu, Diane D.-S., 211Tanigawara, Yusuke, 541

Tatsumi, K., 226Taylor, A. M., 148

Tephly, T. R., 896

AUTHOR INDEX 969

Thai, Gerald, 360

Theoharides, Anthony D., 869

Thijssen, H. H. W., 268

Thomsen, Karin F., 172Tilbrook, G. S.,256

Tocco, Dominick J., 428Tomilo, Mark, 74

Torfg#{227}rd,Kristina E., 553Toth, John E., 958Town, Christopher, 954Tracy, Timothy S., 322Trimble, L., 383

Tse, Francis L. S., 603

Turgeon, Jacques, 762

Tyndale, R. F., 1

Uetrecht, Jack P., 120, 205

Umeda, Shin, 367

Urbanski, James J., 695

Usansky, Joel I., 64Utesch, Dietmar, 614

Vadas, Elizabeth, 428

Van Bezooijen, Cornelis F. A., 502Van Der Greef, J., 941

Van de Vyver, F. L., 507Varga, Ferenc, 234Vaz,AlfinD.N., 108

Vedrine, Yves, 490

Veltman, J. C., 948Venkataramana, D., 909Venkataramanan, Raman V., 572

Vickers, Alison E. M., 56, 802Vince, Robert, 47Voyksner, Robert D., 856

Wallach, David, 592Walle, Thomas, 331

Walle, U. Kristina, 331Walsh,JohnS., 912Watanabe, K., 79Watson, R. William G., 413Weber, Gregory L., 665Wedlund, Peter J., 446

Weidolf, Lars, 262

Weinshilboum, Richard M., 247,

413Weller, Stephen, 679Wells, D. A., 124

White, W. Reid, 856Williams, H., 383Wilson, Alan G. E., 616Wilson, Dennis W., 275

Winter, Steven M., 665Wong,J.M.Y.,465Wong, K. K., 84, 525, 530, 536

Wood, Thomas C., 413

Wrigglesworth, John, 423

Wu,D.,l

Yamada, S., 161Yamamoto, I., 79Yamamoto, Kenji, 816Yang, J. T., 84, 525, 536Yang, Shen K., 719

Yang, Wei, 38

Yergey,J., 383

Yokogawa, Koichi, 485Yoo, S. D., 302

Yoshida, H., 127Yoshida, Takemi, 52

Yoshimura, H., 79Yost, Garold S., 632Young, L. M., 840Ythier, Arnaud, 592Yun, Chul-Ho, 753Yuzawa, Kenji, 773

Zamboni, R., 383

Zbaida, Shmuel, 902Zhang, Lisha, 52Zhang, Ruiwen, 1 13Zheng, Jiang, 688

Zhoo, N-S., 134Ziegler, D. M., 948Zimmerman, Cheryl L., 47

Zimmerman, John L., 958Zollinger, Markus, 56

970

SUBJECT INDEX

A-64077, glucuronidation, hepatic microsomes (humans), 328

Abbott-64662, see Enalkiren

Acetaminophen glucuronide, sulfate and, probenecid-impaired biliary

excretion (rats), 496Acetyl CoA:arylamine N-acetyltransferase, H2-receptor antagonists (rats),

74

N-Acetyltransferase, correlation of activities, uroepithelia, in vivo acety-

lator phenotype (humans), 559a1-Acid glycoprotein, plasma proteins, conjugation of dinitrofluoroben-

zene (rats), 625Acitretin, systemic pharmacokinetics (guinea pigs, rats), 21 1Acquired immunodeficiency syndrome

anti-HIV drugs, CD4, pharmacokinetic evaluation (monkeys), 3963’-azido-3’-deoxythymidine drug interactions (humans), 578

Acrivastine, disposition (dogs), 679Acrylic acid, propionic acid and, urinary metabolites, homonuclear 3C

nuclear magnetic resonance spectroscopy (rats), 665

Acyl glucuronide, metabolism of SK&F 102922 (guinea pigs), 479Aging, pharmacokinetic profile oftheophylline, liver (rabbits), 826

Alachlor, metabolism by liver and nasal turbinate tissue (rats, monkeys),

616Albumin

covalent binding ofetodolac acyl glucuronide, 962

plasma proteins, conjugation ofdinitrofluorobenzene (rats), 625Aldehyde dehydrogenase, substrate specificity, liver (mice), 134Aldehyde oxidase, hepatic, metabolism ofcinchona antimalarials (guinea

pigs, rabbits), 889Aldose reductase, inhibitors ALO-4l 14 and ALO-3152, oxidation, cata-

lyzed by liver microsomes (rats), 948

Alendronatepotent antiosteolytic bisphosphonate (rats), 473renal handling (rats), 608

Allylbenzene, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxidehydrolases (mice, guinea pigs), 440

Amines, tertiary, UDP-glucuronosyltransferases, hepatic microsomes(humans, rabbits), 896

6-Aminocarbovir, pharmacokinetic evaluation as a prodrug, carbovir

(rats), 47

Aminopyrine N-demethylase, caffeine demethylase activity, liver micro-

somes (humans, rats), 343Amphotericin B, disposition (rats), 432

Angiotensin I, pharmacokinetic and pharmacodynamic properties, en-alkiren (humans), 821

Antiarrhythmic agents, glucuronide metabolites of mexiletine, N-oxida-tion and deamination, spectroscopy (rabbits), 762

Antibiotics

hops component colupulone, inducer, hepatic cytochrome P-450 3A

(mice), 142usnic acid, intravenous and oral administration, pharmacokinetics

(rabbits), 909Antiemetic drugs, urinary metabolites of MDL 72,222 (dogs, monkeys),

596Antihypertensive agents, stereoselective disposition ofS-8666, liver prep-

aration (rats), 350Antimalarials, cinchona, role of hepatic aldehyde oxidase, metabolism

(guinea pigs, rabbits), 889Antimicrobial agents, metabolism of sodium nifurstyrenate (rabbits,

guinea pigs, rats, mice, hamsters, fish), 226Antipyrine, theophylline and, metabolism, 3-methylcholanthrene induc-

tion (rats), 502Aryl sulfotransferase IV, hepatic, interactions with N-hydroxy arylamine

(rats), 339Aryl-trifluoromethyl sulfide, specific and enantioselective sulfoxidation,

liver cytochromes P450 (rats), 877

Asthma

aerosolized MK-679, physiological disposition (rats), 428pharmacokinetics and renal handling, enprofylline, pregnancy (rats),

653

Azelastinemetabolism (guinea pigs), 536pharmacokinetics, active metabolite desmethylazelastine (guinea pigs),

530

tissue distribution, lung localization (guinea pigs), 525

3’-Azido-3’-deoxythymidine, drug interactions (humans), 578Azoreductase, microsomal, substrates for, 902

Benz(a)anthracene, fl-naphthoflavone and, induction of CYP1A1mRNA, epidermis and keratinocytes (rats, humans), 620

Benzene

metabolism in hepatocytes, influence ofP-450 2E1 induction, benzenemetabolism (rats), 137

substituted derivatives, inhibition, microsomal cytochrome P-450 2E1-

dependent p-nitrophenob (rabbits), 775Best Paper Award for 1991, 619Bile

metabolite excretion, influence of P-450 2E 1 induction, benzene me-

tabolism (rats), 137metabolites of m-dichborobenzene (rats), 161

probenecid-impaired excretion, acetaminophen glucuronide and sul-

fate (rats), 496Bis(2-ethylhexyl) phthalate, metabolites, glucosidation, new conjugation

pathway, 470Bisphosphonate, antiosteolytic, alendronate (rats), 473Bladder neoplasms, correlation between N-acetyltransferase activities,

uroepithelia, in vivo acetylator phenotype (humans), 559Brain

antagonist of cholecystokinin receptor, physiological disposition, L-365,260 (rats, dogs, monkeys), 390

cytochrome P-450, 446Breast milk, pharmacokinetics ofcaffeine and demethylated metabolites

(rabbits), 302Bromo(monohydroxy)phenyl mercapturic acids, new class of mercap-

turic acids (rats), 688Bunitrolol, 4-hydroxylation, cytochrome P-450 isozyme, liver micro-

somes (rats), 3671 ,3-Butadiene, microsomal oxidation, species and tissue differences

(mice, rats), 6583-tert-Butyl-4-hydroxyanisole, metabolism by horseradish peroxidase,

hydrogen peroxide and, 816

Cadmium, decreased cellular uptake and toxicity, exogenous glutathione,714

Caffeine, demethylated metabolites and, pharmacokinetics, lactatingadult rabbits and neonatal offspring, 302

Caffeine demethylase, activity in liver microsomes (humans, rats), 343Cancer, advanced, pharmacokinetics and pharmacodynamics, topotecan

(humans), 706Carbamoyl, glucuronide conjugate of carvedilol, liver microsomes (dogs,

rats), 130

Carbinolamide, phenolic glucuronide conjugates and, N-methyl-N-(l-methyl-3,3-diphenylpropyl)formamide (rats), 451

Carbon- 13, -labeled xenobiotics, pharmacokinetics, ‘3C-NMR spectros-

copy (rats),507

Carbonyl (phenone)reductase, structure-activity relationship, substrates,liver (humans), 465

Carbonyl reductases, stereoselective acetonyl side chain reduction, war-farm and analogs, 268

Carboviroxidation, liver cytosolic enzymes (rats), 912

SUBJECT INDEX 971

19

pharmacokinetic evaluation, 6-aminocarbovir as prodrug (rats), 47

Carboxyphosphamide, NMR studies of its stability, cell membrane

permeability, 337

Carcinogenesis, metabolism of 4-(methylnitrosamino)-143-pyridyl)-1-butanone, pregnancy and ethanol treatment, liver and lung mi-

crosomes (hamsters), 510Carvedilol, carbamoyl glucuronide conjugate, liver microsomes (dogs,

rats), 130CD4

anti-human immunodeficiency virus drugs, pharmacokinetic evalua-lion (monkeys), 396

metabolically labeled recombinant soluble, intravenous and subcuta-neous administration (rats), 695

Cefoperazone, cephradine and, comparative pharmacokinetics, un-treated streptozotocin diabetic rats, 730

Chinese hamster ovary cells, total body and hepatic clearance, tissue-type plasminogen activator, 541

2-Chboronitrobenzene, 4-chboronitrobenzene and, percutaneous absorp-tion (rats), 436

4-Chloro-5-sulfamoyl anthranilbic acid, microbial models, mammalian

metabolism, 882Cigarette smoking, urinary excretion ofglucuronide conjugates, nicotine,

cotinine and trans-3 ‘-hydroxycotinine (humans), 192Cinchona, antimalarials, role of hepatic aldehyde oxidase, metabolism

(guinea pigs, rabbits), 889Cinobufagin, deacetylation, liver (rats), 52Cocaine

-bioactivating isoform, cytochrome P-4501IB1, hepatic microsomesand hepatocytes (rats), 96

metabolism to norcocaine and N-hydroxynorcocaine, pharmacoki-

netics (mice), 863Coenzyme A

glycine and, limits ofgbycine conjugation in vivo (rats), 234

metabolic inversion of(R)-ibuprofen (rats), 322Coenzyme QlO, tissue concentrations, oral and intraperitoneal admin-

istration (rats), 423Collagen, gels, phenol sulfotransferase activity, liver parenchymal cells

(rats), 614Colupulone, inducer of hepatic cytochrome P-4503A (mice), 142Cotinine, urinary excretion ofglucuronide conjugates, smokers, 192CQA 206-291, N-dealkylation, cytochrome P-450 gene family (humans),

56p-Cresol, metabolic fate of menthofuran (rats), 295Cunninghamella echinulata, biotansformations of N-methylcarbazole,

38Cunninghame/la e/egans, microbial models, mammalian metabolism,

882

Cyanide, in vivo metabolism, methacrylonitrile (rats, mice, gerbils), 156Cyclohexanecarboxylic acid, pharmacokinetics and pharmacodynamics

(rats), 810Cyclophosphamide, ifosfamide and, cytochrome P-450-mediated N-de-

chloroethylation (rats), 770Cyclosporin A, metabolism, liver, kidney and intestine slices (humans,

rats, dogs), 802Cycbosporine, metabolism in liver, low-density lipoprotein, ethinyl estra-

diol (rats), 547CYP1A1, messenger RNA induction, benz(a)anthracene and fl-naphtho-

flavone, epidermis and keratinocytes (rats, humans), 620Cytochrome P450

brain, 446

-dependent activities, interleukin lfl, fetal hepatocytes (rats), 407dominant role in human hepatic microsomal oxidation, l,1,l,2-tetra-

fluoroethane (rats), 5182E2/1A1/1A2, induction by imidazole, neonates (rabbits), 792gene family, N-dealkylation, CQA 206-29 1 (humans), 56genes and subfamilies, phenobarbital and dexamethasone, liver (mice),

797

hepatic and renal, monooxygenases, fuzzy and Sprague-Dawley rats,

isozyme catalyzing bunitrolol 4-hydroxylation, liver microsomes (rats),367

isozymes involved in oxidative metabolism, tetrahydrocannabinol,liver microsomes (rats), 79

liver

enantioselective sulfoxidation, aryl-trifluoromethyl sulfide (rats),877

theophylline metabolism (humans), 31-mediated N-dechloroethylation, cyclophosphamide and ifosfamide

(rats), 770placental aromatase, inhibitors, substituted pyridines (humans), 108

Cytochrome P-4503Acolupulone as inducer (mice), 142enzymes responsible for biotransformation, FK506 and rapamycin

(humans, rats), 753Cytochrome P450 2A2, production of testosterone metabolite, l2a-

hydroxytestosterone, 566

Cytochrome P-450db1, catalytic and immunologic similarities, liver(monkeys, humans), 1

Cytochrome P450 2El-dependent p-nitrophenol hydroxylation, inhibition, substituted ben-

zene derivatives (rabbits), 775influence of induction on benzene metabolism, hepatocytes, biliary

metabolite excretion (rats), 137Cytochrome P-45OIIB1, cocaine-bioactivating isoform, hepatic micro-

somes, hepatocytes (rats), 96Cytochrome P-45011D, subfamily, minaprine 4-hydroxylation, hepatic

microsomes (humans), 316Cytochrome P450 monooxygenase, basal and hydrocarbon-induced,

differential expression, epidermal cells (mice), 360Cytosol

esterases, enantioselectivity, intestinal mucosa (rats), 719liver enzymes, oxidation ofcarbovir (rats), 912stereoselective acetonyl side chain reduction, warfarin and analogs,

268

Debrisoquin, inhibition of clearance in liver, inhibition of dextrome-thorphan, 4-hydroxydebnsoquin (rats, humans), 379

Dehydroepiandrosterone, sulfation of estrone and l7fl-estradiol, liver(humans), 413

Deoxycytidine, analog gemcitabine, metabolism and disposition (mice,

rats, dogs), 849Desmethylazelastine, pharmacokinetics of azelastine (guinea pigs), 530

Dexamethasone, phenobarbital and, cytochrome P-450 genes andsubfamilies, liver (mice), 797

Dextromethorphan, inhibition in liver microsomes, inhibition of debri-

soquin clearance, 4-hydroxydebrisoquin (rats, humans), 379Diabetes, comparative pharmacokinetics, cefoperazone and cephradine

(rats), 730Dibutyryl-cAMP, influence on ibuprofen-induced alterations, sulfate

renal clearance (rats), 461m-Dichlorobenzene, biliary metabolites (rats), 161

6,7-Dichloro-5-(N,N-dimethylsulfamoyl)-2,3-dihydro-2-benzofuran car-boxylic acid, stereoselective renal tubular secretion (monkeys),179

2’,3’-Dideoxycytidine, pharmacokinetic evaluation, CD4, anti-HIVdrugs (monkeys), 396

Diet, deficient intake of sulfur, homeostasis, sulfate and 3’-phosphoad-

enosine 5’-phosphosulfate (rats), 3741,2-Diethyl-3-hydroxypyridin-4-one, pharmacokinetics (rats), 736Dinitrofluorobenzene, conjugation to plasma proteins (rats), 625Diphenyl ether, cleavage of 3-phenoxybenzoic acid, kidney microsomal

preparations (chickens), 356Dipyridine, induction of microsomal epoxide hydrolase, UDP-glucuron-

syltransferase activities (rats), 726Diuretics

stereoselective disposition of S-8666, liver preparation (rats), 350uricosuric, stereoselective renal tubular secretion (monkeys), 179

DuP 753, metabolism in liver slices (rats, monkeys, humans), 281Dyes, substrates for microsomal azoreductase, 902

972 SUBJECT INDEX

Embryo, conceptal retinoid levels, microinjections (rats), 218Enalkiren, pharmacokinetic and pharmacodynamic properties, single

dose study (humans), 821Enflurane, metabolism (dogs), 127Enprofylline, pharmacokinetics and renal handling, pregnancy (rats),

653

Epidermal cells, differential expression, basal and hydrocarbon-inducedcytochrome P450 monooxygenase (mice), 360

Epidermal growth factors, human, pharmacokinetic evaluation (rats), 23Epidermis, keratinocytes and, induction of CYPIA1 mRNA,

benz(a)anthracene and /3-naphthoflavone (rats, humans), 620Epoxide hydrolase, microsomal, UDP-glucuronosyltransferase activities,

induction by dipyridine compounds (rats), 726Epoxide hydrolases, microsomal and cytosolic, hydrolysis, allylic epox-

ides (mice, guinea pigs), 440Ergot, alkaloid CQA 206-29 1 , N-dealkylation, cytochrome P450 gene

family (humans), 56Esterases, microsomal and cytosolic, enantioselectivity, intestinal mucosa

(rats), 719l7fl-Estradiol, estrone and, sulfation, liver (humans), 413Estragole, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide

hydrolases (mice, guinea pigs), 440Estrone, 17$-estradiol and, sulfation, liver (humans), 413Ethanol, pregnancy and, NNK metabolism, liver and lung microsomes

(hamsters), 510Ethinyl estradiol, low-density lipoprotein and, cyclosporine metabolism,

liver (rats), 5472-Ethyl-l,3-hexanediol, pharmacokinetics (rats), 6Etodolac acyl glucuronide, covalent binding to albumin, 962Etretinate, systemic pharmacokinetics (guinea pigs, rats), 21 1Eugenol, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide hy-

drolases (mice, guinea pigs), 440

Felbamate, metabolism (dogs), 84

Fetus, flavin-containing monooxygenase, stereoselective sulfoxidation(humans), 832

Finasteride, disposition and pharmacokinetics, oral administration (hu-mans), 148

FK506, rapamycin and, cytochrome P450 3A enzymes, biotransfor-mation (humans, rats), 753

Flavin, -containing monooxygenase, stereoselective sulfoxidation (hu-mans), 832

2-Fluoro-fi-alanine, pharmacokinetics and tissue distribution (rats), 113

5-Fluorouracil, toxicity pattern, pharmacokinetics of 2-fluoro-fi-alanine(rats), 113

N-Formylmethamphetamine, carbinolamide and phenolic glucuronide

conjugates, N-methyl-N-(1-methyl-3,3-diphenylpropyl)forma-mide(rats), 451

Ftorafur, uracil and, clinical pharmacology (humans), 936Furfural, furfural alcohol and, comparative metabolism, disposition

(rats), 198Furosemide, N-dealkylation, microbial models, mammalian metabolism,

882

Gemcitabine, metabolism and disposition (mice, rats, dogs), 849

Gentamicin, obesity as risk factor, drug-induced organ injury (rats), 402a-Glucoside, formation of xenobiotics, liver (rats), 309Glucuronide

metabolites ofmexiletine, N-oxidation and deamination, spectroscopy(rabbits), 762

phenolic conjugates and carbinolamide, N-methyl-N-(l-methyl-3,3-diphenylpropyl)formamide (rats), 451

Glutathioneconjugation, metabolic route of omeprazole (rats), 262conjugation of butadiene monoxide, species differences (mice, rats),

658

exogenous, decreased cellular cadmium uptake and toxicity, 714

Glyceryl trinitrate, 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate, tissuedisposition (rats), 553

Glycine, coenzyme A and, limits to glycine conjugation in vivo (rats),234

Heart, tissue concentrations of coenzyme Q 10 (rats), 423Hepatocytes

benzene metabolism, influence of P-4502E1 induction, biliary metab-olite excretion (rats), 137

cocaine-bioactivating isoform, cytochrome P-45011B1 (rats), 96differential effects of interleukin lfl, cytochrome P450-dependent

activities (rats), 407Hepatomegaly, peroxisome proliferators, commentary on a symposium,

779

High performance liquid chromatography, -atmospheric pressure ioni-zation mass spectrometry, conjugated metabolites, 4-hydroxyan-

drost-4-ene-3,l7-dione, 941Hops, colupulone, inducer, hepatic cytochrome P-4503A (mice), 142

Horseradish peroxidase, hydrogen peroxide and, 3-tert-butyl-4-hydroxy-anisole metabolism, 816

H2-receptor antagonists, liver cytosolic acetyl CoA:arylamine N-acetyl-

transferase (rats), 74Human immunodeficiency virus

anti-HIV drugs, CD4, pharmacokinetic evaluation (monkeys), 396Tat inhibitor Ro 5-3335, disposition (rats, dogs), 954

Human immunodeficiency virus-l, inhibitor L-696,229, metabolism inliver slices (rats), 869

Hydrocarbon, -induced cytochrome P-450 monooxygenase, differential

expression, epidermal cells (mice), 360Hydrogen peroxide, horseradish peroxidase and, 3-tert-butyl-4-hydroxy-

anisole metabolism, 8164-Hydroxyandrost-4-ene-3,l7-dione, conjugated metabolites in urine,

liquid chromatography-atmospheric pressure ionization mass

spectrometry, 941N-Hydroxy arylamine, interactions with hepatic aryl sulfotransferase IV

(rats), 339

trans-3 ‘-Hydroxycotinine, urinary excretion of glucuronide conjugates,smokers, 192

4-Hydroxydebrisoquin, inhibition ofdextromethrophan metabolism, in-

hibition ofdebrisoquin clearance, liver (rats, humans), 379N-Hydroxynorcocaine, metabolism of cocaine, pharmacokinetics (mice),

8634-Hydroxypropranolol, terbutaline and, stereoselective sulfate conjuga-

tion, liver phenosulfotransferases (humans), 3333-Hydroxypyridin-4-ones, 1,2-dimethyl- and 1,2-diethyl-substituted, un-

nary metabolic profiles (humans, rats), 256I 2a-Hydroxytestosterone, testosterone metabolite, production by cyto-

chrome P450 2A2, 566

Ibuprofen, -induced alterations, dibutyryl-cAMP, sulfate renal clearance

(rats), 461(R)-Ibuprofen, metabolic inversion (rats), 322Ictalurus punctatus, disposition of 1-naphthol, 70

Ifosfamide, cyclophosphamide and, cytochrome P450-mediated N-dc-

chloroethylation (rats), 770Imidazole, induction of P-450 cytochromes, neonates (rabbits), 792

Immunosuppression, isolation of rapamycin metabolites (humans), 186Indenesulfonylureas, formation, metabolism ofsulofenur (rats, monkeys,

humans), 958Interleukin 1f3, cytochrome P450-dependent activities, differential ef-

fects, fetal hepatocytes (rats), 407Intestine

cyclosporin A metabolism (humans, rats, dogs), 802mucosa, enantioselectivity, microsomal and cytosolic esterases (rats),

719

Ischemia, liver, trimethadione metabolism, index ofhepatic drug-oxidiz-ing capacity (dogs), 773

Isoniazid, metabolism by activated leukocytes (humans), 2054-[2-(4-Isopropylbenzamido)ethoxy]benzoic acid, enterohepatic circula-

tion (rats),585

Isotretinoin, systemic pharmacokinetics (guinea pigs, rats), 21 1

SUBJECT INDEX 973

Keratinocytes, epidermis and, induction of CYP1A1 mRNA,

benz(a)anthracene and fl-naphthoflavone (rats, humans), 620Kidney

cyclosporin A metabolism (humans, rats, dogs), 802cytochromes P-450-dependent monooxygenases, fuzzy and Sprague-

Dawley rats, 19flavin-containing monooxygenase, stereoselective sulfoxidation (hu-

mans), 832handling of alendronate (rats), 608

microsomes, diphenyl ether cleavage, 3-phenoxybenzoic acid (chick-

ens), 356renal handling and pharmacokinetics, enprofylline, pregnancy (rats),

653

stereoselective tubular secretion, uricosuric diuretics (monkeys), 179

sulfate clearance, ibuprofen-induced alterations, dibutyryl-cAMP

(rats), 461

tissue concentrations ofcoenzyme Ql0 (rats), 423

L-365,260, physiological disposition and metabolism (rats, dogs, mon-

keys), 390L-696,229, metabolism in liver slices (rats), 869Lactation, pharmacokinetics of caffeine and demethylated metabolites

(rabbits), 302Leukocytes

activated, metabolism of isoniazid (humans), 205

comparative metabolism and covalent binding, procainamide (hu-

mans), 120Leukotriene D4, antagonist verlukast, biotransformations (rats), 383

Lichens, intravenous and oral administration, usnic acid, pharmacoki-netics (rabbits), 909

Lipoprotein, low-density, ethinyl estradiol and, cyclosponine metabolism

in liver (rats), 547Liver

aryl sulfotransferase IV, interactions of N-hydroxy arylamine (rats),

339carbonyl (phenone) reductase, structure-activity relationship, sub-

strates (humans), 465clearance of tissue-type plasminogen activator, mouse Cl 27 and CHO

cells, 541

cyclosporin A metabolism (humans, rats, dogs), 802cyclosporine metabolism, low-density lipoprotein, ethinyl estradiol

(rats), 547

cytochrome P450db1, catalytic and immunologic similarities (mon-keys, humans), I

cytochromes P-450

enantioselective sulfoxidation, aryl-tnifluoromethyl sulfide (rats),

877theophylline metabolism (humans), 31

cytochromes P450-dependent monooxygenases, fuzzy and Sprague-

Dawley rats, 19cytosolic acetyl CoA:arylamine N-acetyltransferase, H2-receptor antag-

onists (rats), 74cytosolic enzymes, oxidation of carbovir (rats), 912

deacetylation of cinobufagin (rats), 52drug metabolism enzymes, lack ofeffect, streptogramins (rats), 490enterohepatic circulation, 4-[2-(4-isopropylbenzamido)ethoxy]benzoic

acid (rats), 585

expression of cytochrome P-450 genes and subfamilies, phenobarbitaland dexamethasone (mice), 797

a-glucosidases, a-glucoside formation, xenobiotics (rats), 309inhibition of clearance, inhibition of dextromethrophan, 4-hydroxy-

debrisoquin (rats, humans), 379intravenously injected platinum complex, pharmacokinetics (mice),

673ischemia, trimethadione metabolism, index of hepatic drug-oxidizing

capacity (dogs), 773metabolism of DuP 753 (rats, monkeys, humans), 281

metabolism of L-696,229 (rats), 869nasal turbinate tissue and, metabolism of alachlor (rats, monkeys), 616

parenchymal cells, phenol sulfotransferase activity, collagen gels (rats),614

pharmacokinetic profile of theophylline, different ages (rabbits), 826

phenosulfotransferases, sulfate conjugation, 4-hydroxypropranolol andterbutaline (humans), 333

stereoselective disposition of S-8666 (rats), 350

substrate specificity, novel aldehyde dehydrogenase (mice), 134sulfation of estrone and l7�9-estradiol (humans), 413

Liver microsomes3’-azido-3’-deoxythymidine drug interactions (humans), 578

caffeine demethylase activity (humans, rats), 343

carbamoyl glucuronide conjugate, carvedilol (dogs, rats), 130cocaine-bioactivating isoform, cytochrome P45OIIB1 (rats), 96cytochrome P450 isozyme

catalyzation, bunitrolol 4-hydroxylation (rats), 367oxidative metabolism, tetrahydrocannabinol (rats), 79

effects of pregnancy and ethanol treatment, metabolism, 4-(methylni-trosamino)-1-(3-pyridyl) -1-butanone (hamsters), 510

epoxide hydrolases, hydrolysis, allylic epoxides (mice, guinea pigs),440

flavin-containing monooxygenase, stereoselective sulfoxidation (hu-mans), 832

glucuronidation, NNC 0756 and NNC 0772 (rats), 172

glucuronidation of Zileutron (humans), 328involvement ofcytochrome P4SOIID subfamily, minaprine 4-hydrox-

ylation (humans), 316

metabolism of 7-( 1,3-thiazolidin-2-ylmethyl)theophylline (rats), 742metabolism of monocrotaline (guinea pigs, rats), 275metabolism of tetrahydrocannabinol (humans), 241

oxidation, cytochrome P450, 1,1,1,2-tetrafluoroethane (rats), 518oxidation of aldose reductase inhibitors (rats), 948

substrates for microsomal azoreductase, 902

tertiary amine UDP-glucuronosyltransferases (humans, rabbits), 896thiol methyltransferase, assay conditions, biochemical properties (hu-

mans), 247Lung, localization, tissue distribution, azelastine (guinea pigs), 525Lung microsomes, effects of pregnancy and ethanol treatment, metabo-

lism, 4-(methylnitrosamino)-143-pyridyl)-1-butanone (hamsters),

510Lupus, metabolism of isoniazid, activated leukocytes (humans), 205LY228729, disposition (monkeys, rats), 102

MDL 28,050, metabolism (rats), 89MDL 72,222, urinary metabolites (dogs, monkeys), 596

Menthofuran, metabolic fate (rats), 295Methacrylonitnile, in vivo metabolism to cyanide (rats, mice, gerbils),

156

Methamphetamine, oral, pharmacokinetics, repeated daily dosing (hu-

mans), 856Methylacrylonitrile, disposition, novel exhaled metabolite (rats), 643Methylazoxyprocarbazine, chemical decomposition products, character-

ization (humans), 632N-Methylcarbazole, biotransformations, Cunninghamella echinulata, 38

3-Methylcholanthrene, induction, metabolism, antipynine and theoph-

ylline (rats), 502I-Methyl- 1-cyclohexanecarboxylic acid, pharmacokinetics and pharma-

codynamics (rats), 810

4-(Methylnitrosamino)-1-(3-pyridyl)-l-butanone, effects of pregnancyand ethanol treatment, liver and lung microsomes (hamsters), 510

N-Methylpyrrolidinone, major urinary metabolite (rats), 124Metyrapone, urinary metabolic profile (rats), 64Mexiletine, glucuronide metabolites, N-oxidation and deamination, spec-

troscopy (rabbits), 762

Miconazole, warfarin disposition (rabbits), 572Microsomes

cytosolic esterases and, enantioselectivity, intestinal mucosa (rats), 719epoxide hydrolase, UDP-glucuronosyltransferase activities, induction

by dipyridine compounds (rats), 726liver,see Liver microsomes

974 SUBJECT INDEX

Spleendistribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin (mice), 467

oxidation of 1,3-butadiene, species and tissue differences (mice, rats),658

Milk, pharmacokinetics of caffeine and demethylated metabolites (rab-bits), 302

MK-679, aerosolized, physiological disposition (rats), 428Monocrotaline, hepatic microsomal metabolism (guinea pigs, rats), 275

Monooxygenaseflavin-containing, stereoselective sulfoxidation (humans), 832hepatic and renal cytochromes P450-dependent, fuzzy and Sprague-

Dawley rats, 19

fl-Naphthofiavone, benz(a)anthracene and, induction of CYP1A1mRNA, epidermis and keratinocytes (rats, humans), 620

l-Naphthol, disposition in channel catfish, 70Neonate, induction of P450 cytochromes, imidazole (rabbits), 792Nicotine, urinary excretion of glucuronide conjugates, smokers, 192p-Nitrophenol, cytochrome P450 2El-dependent hydroxylation, inhi-

bition, substituted benzene derivatives (rabbits), 775N-Methyl-N-( 1-methyl-3,3-diphenylpropyl)formamide, carbinolamide

and phenolic glucuronide conjugates (rats), 451NNC 0756, NNC 0772 and, glucuronidation, liver microsomes (rats),

172Norcocaine, metabolism ofcocaine, pharmacokinetics (mice), 863Nose, nasal turbinate tissue and liver, metabolism of alachbor (rats,

monkeys), 616Nuclear magnetic resonance

carbinolamide and phenolic glucuronide conjugates, N-methyl-N-( 1-methyl-3,3-diphenylpropyl)formamide (rats), 451

stability and cell membrane permeability, carboxyphosphamide, 337substrates for microsomal azoreductase, 902

Nuclear magnetic resonance spectroscopy13C, pharmacokinetics, ‘3C-labeled xenobiotics (rats), 507

glucuronide metabolites of mexiletine, N-oxidation and deamination(rabbits),762

urinary metabolites, acrylic acid and propionic acid (rats), 665

Obesity, risk factor in drug-induced organ injury (rats), 402Omeprazole, metabolic route, glutathione conjugation (rats), 262

Osteoporosis, alendronate, potent antiosteolytic bisphosphonate (rats),

473

Peroxisome, proliferators, commentary on a symposium, 779Phenobarbital, dexamethasone and, cytochrome P450 genes and

subfamilies, liver (mice), 797

Phenol sulfotransferaseactivity in liver parenchymal cells, collagen gels (rats), 614liver, sulfate conjugation, 4-hydroxypropranolol and terbutaline (hu-

mans), 333

sulfation of estrone and l7fl-estradiol, liver (humans), 4133-Phenoxybenzoic acid, diphenyl ether cleavage, kidney microsomal

preparations (chickens), 3565-(2-(8-Phenyloctyl)phenyl)-4,6-dithianonanedioic acid, metabolism

(guinea pigs), 4793’-Phosphoadenosine 5’-phosphosulfate, sulfate and, homeostasis, defi-

cient dietary intake of sulfur (rats), 374

9-(2-Phosphonylmethoxyethyl)adenine, pharmacokinetics (mice), 747Placenta, inhibitors of aromatase cytochrome P450, substituted pyni-

dines (humans), 108Plasma, proteins, conjugation of dinitrofluorobenzene (rats), 625

Plasminogen activator, tissue-type, total body and hepatic clearance,mouse C I 27 and CHO cells, 541

Pregnancy

ethanol treatment and, NNK metabolism, liver and lung microsomes

(hamsters), 510

pharmacokinetics and renal handling, enprofylline (rats), 653

Probenecid, -impaired biliary excretion, acetaminophen glucuronide andsulfate (rats), 496

Procainamide, comparative metabolism and covalent binding, leuko-cytes (humans), 120

ProcarbazineBest Paper Award for 199 1, 619

chemical decomposition products, methylazoxyprocarbazine, charac-terization (humans), 632

Propionic acid, acrylic acid and, urinary metabolites, homonuclear 13Cnuclear magnetic resonance spectroscopy (rats), 665

Propranolol, pharmacokinetics and metabolism, influence of vitamin K3(rats), 288

Prough, Russell A., Best Paper Award for 199 1, 619

Pyridines, substituted, inhibitors, placental aromatase cytochrome P450

(humans), 108

Quinine, metabolism ofcinchona antimalarials, role ofhepatic aldehydeoxidase (guinea pigs, rabbits), 889

Quinone, tissue concentrations ofcoenzyme QlO (rats), 423

Quinone reductase, basal and hydrocarbon-induced cytochrome P450

monooxygenase, differential expression, epidermab cells (mice),360

Quinuclidinyl benzylate, physiologically based pharmacokinetic model,

nonlinear tissue binding parameters (rats), 485

RapamycinFK506 and, cytochrome P450 3A enzymes, biotransformation (hu-

mans, rats), 753isolation of immunosuppressive metabolites (humans), 186

Receptorsangiotensin II, antagonist DuP 753, metabolism in liver slices (rats,

monkeys, humans), 281

cholecystokinin, antagonist L-365,260, physiological disposition (rats,dogs, monkeys), 390

dopamine D-1, antagonists NNC 0756 and NNC 0772, liver micro-somes(rats), 172

leukotniene, antagonist SK&F 102922, metabolism (guinea pigs), 479

Renin, inhibitor enalkiren, pharmacokinetic and pharmacodynamicproperties (humans), 821

I 3-cis-Retinoic acid, all-trans-retinoic acid and, conceptal retinoid levels,microinjections (rats), 218

Retinoids, acetylenic, systemic pharmacokinetics (guinea pigs, rats), 21 1Retinol, conceptal retinoid levels, microinjections (rats), 218all-trans-Retinoyl-$-glucuronide, conceptal retinoid levels, microinjec-

tions (rats), 218

Retrovirus, anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine,pharmacokinetics (mice), 747

RNA, messenger, induction ofCYP1A 1, benz(a)anthracene and fi-naph-thoflavone, epidermis and keratinocytes (rats, humans), 620

Ro 5-3335, disposition (rats, dogs), 954

S-8666

stereoselective disposition, liver preparation (rats), 350stereoselective renal tubular secretion (monkeys), 179

Safrole, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide hy-drolases (mice, guinea pigs), 440

Serotonin

agonist LY228729, disposition (monkeys, rats), 102

antagonist MDL 72,222, urinary metabolites (dogs, monkeys), 596

antagonist tropisetron, pharmacokinetics, metabolism (humans), 603SK&F 102922, metabolism (guinea pigs), 479Skin

differential expression in epidermal cells, basal and hydrocarbon-induced cytochrome P450 monooxygenase (mice), 360

hepatic and renal cytochromes P450, monooxygenases, fuzzy andSprague-Dawley rats, 19

pharmacokinetics of 2-ethyl-l,3-hexanediol (rats), 6Sodium nifurstyrenate, metabolism (rabbits, guinea pigs, rats, mice,

hamsters, fish), 226Sparteine, metabolites (humans), 330Species differences, microsomal oxidation of 1,3-butadiene (mice, rats),

658

SUBJECT INDEX 975

Zileutron, glucuronidation, hepatic microsomes (humans), 328

intravenously injected platinum complex, pharmacokinetics (mice),

673

Streptogramins, lack of effect, hepatic drug metabolism enzymes (rats),

490Streptozotocin, untreated diabetic rats, comparative pharmacokinetics,

cefoperazone and cephradine (rats), 730Sulfate

3 ‘-phosphoadenosine 5 ‘-phosphosulfate and, homeostasis, deficient

dietary intake of sulfur (rats), 374renal clearance, ibuprofen-induced alterations, dibutyryl-cAMP (rats),

461Sulofenur, metabolism, formation ofindenesulfonylureas(rats, monkeys,

humans), 958

T cells, metabolically labeled recombinant soluble CD4, intravenous andsubcutaneous administration (rats), 695

Terbutaline, 4-hydroxypropranolol and, stereoselective sulfate conjuga-

tion, liver phenosulfotransferases (humans), 333Testosterone, metabolite 12a-hydroxytestosterone, production by cyto-

chrome P450 2A2, 566Tetrachloro(D,L-trans)l ,2-diaminocyclohexane platinum(IV), intrave-

nously injected, pharmacokinetics (mice), 6732,3,7,8-Tetrachlorodibenzo-p-dioxin, distribution in splenic tissue

(mice), 4671,1,1,2-Tetrafluoroethane, dominant role of cytochrome P-450, human

hepatic microsomab oxidation (rats), 518

Tetrahydrocannabinolhepatic microsomal metabolism (humans), 241oxidative metabolism, cytochrome P-450 isozymes, liver microsomes

(rats), 79

Theophyllineantipyrine and, metabolism, 3-methylcholanthrene induction (rats),

502

metabolism, liver cytochromes P450 (humans), 31pharmacokinetic profile, different ages, liver (rabbits), 826

7-( 1,3-Thiazolidin-2-ylmethyl)theophylline, metabolism in liver micro-

somes (rats), 742Thiol methyltransferase, hepatic microsomal, assay conditions, biochem-

ical properties (humans), 247Topotecan, pharmacokinetics and pharmacodynamics, advanced cancer

(humans), 706

Tranquilizers, characterization of xylazine metabolites (rats), 840Tnimethadione, metabolism as index of hepatic drug-oxidizing capacity,

liver ischemia (dogs), 773Triprolidine

disposition and metabolism (mice), 920disposition (dogs), 928

Tropisetron, pharmacokinetics and metabolism (humans), 603

Tumor necrosis factor, binding protein, human urinary tumor, phar-macokinetics (mice), 592

Tweedie, Donald J., Best Paper Award for 1991, 619

UDP-glucuronosyltransferase

hepatic microsomes (humans, rabbits), 896microsomal epoxide hydrolase and, induction by dipyndine com-

pounds (rats), 726Uracil, ftorafur and, clinical pharmacology (humans), 936

Uric acid, stereoselective disposition of 5-8666, liver preparation (rats),350

Urinary neoplasms, tumor necrosis factor binding protein, pharmacoki-

netics (mice), 592Uroepithelia, in vivo acetylator phenotype, correlation, ‘,6’-dimethyl-

phenylamino)-4-oxo-5.6-dihydro-1,3-thiazineN-acetyltransferase

activities (humans), 559

Usnic acid, intravenous and oral administration, pharmacokinetics (rab-

bits), 909

Valproate analogs, pharmacokinetics and pharmacodynamics (rats), 810

Verlukast, biotransformations (rats), 383Vitamin K3, influence on pharmacokinetics and metabolism, proprano-

lol (rats), 288

Warfarin

analogs and, stereoselective acetonyl side chain reduction, 268disposition, effect of miconazole (rabbits), 572

Xenobiotics3C-labeled, noninvasive in vivo ‘3C-NMR spectroscopy (rats), 507

a-glucoside formation, liver, a-glucosidases (rats), 309Xylazine, characterization of metabolites (rats), 840

INSTRUCTIONS TO AUTHORS

Submission of manuscripts. Drug Metabolism and Dis-

position will review in vitro and in vivo experimental

results that contribute significant and original information

on xenobiotic metabolism and disposition. The term xen-

obiotic includes pharmacologic agents as well as environ-

mental chemicals. Pharmacokinetic and pharmacody-

namic manuscripts and those involving mechanisms are

invited. Manuscripts concerned with factors which affect

the biological fate ofchemicals such as genetic, nutritional

or hormonal are of interest. Papers addressing toxicologi-

cal consequences of xenobiotic metabolism are appropn-

ate.

Three copies of each manuscript should be sent to Dr.

Vincent G. Zannoni, Editor, Drug Metabolism and Dis-

position, Department of Pharmacology, University of

Michigan Medical School, MSI, Ann Arbor, Michigan

48109-0626. FAX number: (313)-763-4450. Submission

ofa manuscript implies that the material contained therein

has not previously been published except as an abstract

for a scientific meeting, and that it is not being submitted

elsewhere.

All manuscripts received in the editorial office must be

accompanied either by a check for $40.00 (in U.S. fundspayable to ASPET) or by a validated purchase order form

from the author’s institution. The review process for sub-

mitted manuscripts will be delayed until the manuscript

handling fee or purchase order form is received in the

Editor’s office. If the submission of the manuscript hand-

ling fee entails a personal financial hardship to the au-

thor(s), the manuscript handling fee will be waived. In

that event, the authors should submit a request for waiver

ofthe fee at the time the manuscript is submitted.

If and when manuscripts are accepted for publication,it will be necessary for the American Society for Pharma-

cology and Experimental Therapeutics, Inc., to receive in

writing assignment of copyright from all authors of each

manuscript. The exception would be when the work was

done by employees ofU.S. federal government. The forms

for this assignment will be mailed from the Editorial

Office. Ifthe original copyright belongs to an agency other

than the authors, the assignment form must be signed by

the proper authority, with an attached document indicat-

ing the nature of the copyright agreement.

After Acceptance: When an article has been accepted

for publication, the final manuscript may be sent to the

Editorial Office on diskette. A hard copy must accompany

the diskette. This will expedite the publication process for

Williams & Wilkins.

Authors are encouraged to submit electronic diskettes

of the final version of their manuscripts along with the

typed REVISED manuscript. Diskettes produced on IBM

or IBM-compatible computers are preferred, but those

produced on most Apple/Macintosh or Wang computers

can also be converted. The following word processing

programs are preferred: XyWrite III Plus, Word Perfect4.2, 5.0, or 5. 1 (IBM or Macintosh), Microsoft Word (IBM

or Macintosh), Wang 015 (WPS), and Wordstar (IBM).

Among other word processing systems that we can convert

are CPT 8000, MacWrite 2.2 or 4.5, Display Write 3 or 4,

Multimate, PC Write, Volkswriter, and Write Now. Au-

thors preparing diskettes on Macintosh computers should

not use the Fast Save option. Files in ASCII can also be

used, but are not preferred. Identify the diskette by pro-

vidingjournal name, manuscript number, senior author’s

name, manuscript title, name of computer file, type of

hardware, operating system and version number, and soft-

ware program and version number.

The journal does not assume responsibility for errors in

conversion of customized software, newly released soft-

ware, and special characters. Mathematics and tabular

material will be processed in the traditional manner.

Form and style of manuscript. Manuscripts, in Englishlanguage only, should be typewritten double-spaced with

ample margins, on one side of 8.5 x 1 1-inch pages. The

original typescript and two copies, which may be Xerox

or other good reproductions, or legible carbon copies,

should be sent. All pages should be numbered in sequence,

starting with the title page.

A. Full-length papers should be arranged as follows:1 . Title page, containing the title of the paper, names

of all authors, and the institution(s) where the work was

done. The title should have no footnote numbers (see

Footnotes below). The title should briefly yet explicitly

indicate the contents ofthe paper. Names ofchemicals or

chemical classes studied, species used, etc., should be

included in the title.

2. Running title not exceeding 50 total characters and

spaces. The name and address of the person to whom

editorial correspondence and galley proofs should be sent

should appear at the bottom of this page.

3. Abstract of not more than 250 words.

4. Introduction. A brief summary of the pertinent lit-erature and a statement of the aims of the work.

5. Materials and Methods. Species, strains, sexes, and

ages or sizes of animals, with Latin names where required

for distinction, should be given. Sources and purities of

chemicals other than common reagents should be mdi-cated. Equipment used and conditions of use should be

specified. When published methods are used, a biblio-

graphic reference is sufficient; minor modifications should

be described. When a method has been extensively mod-

ified, the entire new procedure should be described. Au-

thors should attempt to describe their work in all cases so

that their peers would be able to repeat the experiments.

Where conditions for similar experiments vary throughout

the work, these may be indicated in legends to figures and

tables. Properties and proof of structure must be given forreference compounds used for metabolite identification.

6. Results. These should be presented as much as pos-sible in graphic and tabular form. When, however, a table

would include only two or three values, it may be prefer-

able to present the data in sentence form in the text.

Authors should avoid using several tables describing very

similar experiments; these should be combined whereverpossible, unless this would result in overcomplicated, un-

wieldy tables. The same data should normally not be

repeated in tables and figures. The text should be used to

describe and summarize the data and to draw primary

conclusions from them, but not to repeat the numerical

data. No extended discussion of the results should be

included in this section.

7. Discussion. The major conclusions to be drawn from

the work should be assembled here, and these should be

discussed with respect to the existing body of knowledge

in the immediate area. Graphic schema should be used

wherever possible to clarify the conclusions. Speculation

should be clearly identified as such, and should be germane

to the data presented. Questions raised by the work, or

those inherent in the experiments, should be discussed.

Although it is normally preferable to separate the Re-

sults and Discussion sections, these sections, e.g. , when an

extended discussion ofsome ofthe experiments is required

for an understanding of subsequent experiments, may

have to be combined occasionally.

8. Acknowledgments oftechnical assistance, gifts of ma-

terials, and other aid. Financial support should not be

mentioned here, but rather in an unnumbered footnote to

the title (see Footnotes, below).

9. References, numbered in order ofcitation in the text.

Examples of style of references follow:

1 . S. S. Lau, G. D. Abrams, and V. G. Zannoni: Metabolic

activation and detoxification of bromobenzene leading

to cytotoxicity. I Pharmacol. Exp. Ther. 214, 703-708(1980).

2. T. C. Butler: The distribution ofdrugs. In “Fundamen-

tals of Drug Metabolism and Drug Disposition” (B. N.

La Du, H. G. Mandel, and E. L. Way, eds.), pp. 44-

62. Williams & Wilkins, Baltimore, 1 97 1.

Papers that have actually been accepted for publication

may be cited among the references; give authors, journal

name, and the words “in press.” Work not published or

accepted, or personal communications, should be cited by

footnote. Where knowledge ofunpublished work is crucial

to evaluation of a paper, duplicate copies of the pertinent

data should be submitted with the manuscript for exami-

nation by the referees.

Authors are urged to exercise the utmost care that

references are accurate. As a rule, references should not

be included that have not been examined personally by

the author. When, because of its rarity of language, the

primary reference could not be examined, the secondary

source should be indicated as well, as follows:

4. K. Maemoto, N. Seike, and M. Hirata, Kobunshi Ka-

gaku 15, 660 (1958); Chem. Abstr. 54, 14775 (1960).

References should be cited in the text by numbers within

parentheses. Abbreviations of journal names should be

those given in Index Medicus.

10. Footnotes, presented in the following order:(a) Unnumbered footnote giving source of financial

support, thesis information, citation of abstracts of meet-

ings where this work was presented, etc., and, in a separate

paragraph, the name and full address (with street address

or P.O. box where applicable, and zip code number) of

person to receive reprint requests.

(b) Numbered footnotes, starting with those (if any) to

authors’ names. Number footnotes in sequence through-

out the text, using superscript numbers.

1 1 . Tables, each on a separate page. Tables are to be

numbered with arabic numbers. The title should be in

italics (or underlined) with only the first word and proper

names capitalized. General statements about the table

should follow the title in paragraph form. Footnotes to

the table should be indicated by italicized lower case

superscript letters, starting with a for each table. Footnotes

should be typed immediately below each table.

1 2. Legends for figures. Figures should be numbered

with arabic numbers, followed by the title in italics (or

underlined), with only the first word and proper nouns

capitalized. The remainder of the explanatory material

should be in paragraph form below the title.

1 3. Index terms. A list of index terms which may be

used in constructing the annual index should constitute

the last typed page of the manuscript.

14. Figures should be submitted with the original

typescript as unmounted glossy photographic prints no

larger than 8 x 10 inches (20 x 25 cm). Xerox or other

good reproductions of line prints may accompany the

other two copies of the manuscript; in the case of half-

tone material, three photographic prints should be sent.

Letters, numbers, and symbols must be large enough to

be readily legible after reduction to single-column size;

these should be at least 1 .5 mm high after reduction. The

style of figures should be uniform throughout the paper.

Figures should be simple and uncluttered, so that they are

readily understandable- after reduction in size. Thus, in

line graphs with multiple lines, it is usually preferable to

use different symbols for the experimental points for dif-

ferent lines, with the explanation ofsymbols in the legend,

rather than to attempt to label individual lines. Abscissa

and ordinate should be clearly labeled with scale, name,

and dimensions of quantities expressed.

B. Short Communications. Short Communications

should not be divided into the sections appropriate for full

papers and should not contain more than 1000 words.

However, they are subject to the same review process as

are full papers. No abstract is required. The first paragraph

should give an introduction to the work. The experiments

and results should be described in narrative fashion. A

moderate amount oftabular and graphic material may be

presented, but the total space allotted to a Communication

may not exceed three printed pages. Structural formulae

of parent compounds and metabolites should be given;

where possible, these should be general formulae with

variable groups identified in a legend.

Title, authors’ names and affiliations, footnotes, cap-

tions, legends, references, and index terms should follow

the forms outlined above for full papers.

C. Reviews. Occasional brief reviews will be published,covering rather limited aspects of a subject in the area of

interest of this journal. These may most typically be

critical reviews that present the author’s view ofthe current

state of the subject, or prospective articles intended to

stimulate discussion and research.

D. Letters. Letters to the editor are invited, in which

relevant work described in this or other journals is dis-

cussed, interesting points raised as suggestions for further

work, or new interpretations ofexisting data made. Where

appropriate, authors of papers to which reference is made

will be invited to reply. Letters presenting new data will

not normally be accepted.

E. National Auxiliary Publications Service (N.A.P.S.).In some cases, results of investigations may be of archival

value, but present insufficient new information of general

interest to the scientific community in terms of method-

ology, types of pathway, significant species differences,

interrelationships with other pharmacologic or toxicologic

properties, etc., to warrant publication in extended form.For deposit with the National Auxiliary Publications Serv-ice (N. A. P. 5.), the data must be submitted in triplicate

with the manuscript. The original copy for the documen-

tary material will be deposited with N. A. P. S. and theaccession number will be published.

Abbreviations for units of measurement should be Un-punctuated, with no distinction between singular and

plural forms. Multiples of units should be indicated as

follows: kg, g, mg, �g (not ug, mcg, or ‘y), ng, pg. Abbre-

viations to be used for units of measurement are:

Mass: g (gram); mol (mole); eq (equivalent). Do not use

M as an abbreviation for mole, as M is used solely as the

concentration term molar.Concentration: M (molar); N (normal); % (percent). In

the latter case, the basis offormulation should be indicated

as % (w/w), % (w/v), or % (v/v) to signify g/ 100 g, g/ 100ml, or ml/lOO ml. The term mg% should not be used.Mixtures should be shown as, for example: acetone/0.5 MKCI/glacial acetic acid, 1:5:2 (v/v).

Length: m (meter); j�m (micrometer). Where commonusage dictates, A (Angstrom) may be used.

Volume: liter should be spelled out, to avoid confusionwith the numeral 1 . Abbreviate compound words contain-

ing the root liter, as ml, �sl, etc.Time: hr (hour); mm (minute); sec (second). Days and

longer units of time should be spelled out.

Radioactivity: Ci (curie); r (roentgen); cpm or dpm

(counts or disintegrations per mm).Electricity: V (volt); amp (ampere); Hz (cycles/sec).

Spectrometry: A#{231}� [absorbance (not OD or E) at 000nm (not m�t) wavelength]; e (molar absorption coefficient,

with units M cm); UV (ultraviolet); IR (infrared); ESR

(electron-spin resonance); NMR (nuclear magnetic reso-

nance); t5 [chemical shift, with units ppm (parts per mu-

lion)]; s (singlet); d (doublet); t (triplet); m (multiplet);

amu (atomic mass units); m/z (mass/charge ratio).

Chromatography: TLC (thin-layer chromatography); RF(retardation factor); GLC (gas-liquid chromatography); RT

(retention time); GC/MS (coupled gas chromatography-

mass spectrometry); HPLC (high-pressure liquid chroma-

tography).

Equilibrium and kinetic constants: Kd (dissociation con-

stant); IC or K, (dissociation constant of enzyme-substrateor enzyme-inhibitor complex); KM (Michaelis constant);

Vmax (maximum initial velocity); k (rate constant); pK,�

(negative logarithm of acidic dissociation constant); t112,

half-life; AUC, area under the curve ofplasma concentra-

tions vs. time.

Statistics: p (probability of chance observation); N

(number of experiments); SD (standard deviation of the

series); SE (standard error of the mean).

Other abbreviations: #{176}C(degrees of temperature); g (ac-celeration due to gravity, as in 9000g); rpm (revolutions

per mm); LD50 and ED50 (median lethal and effective

doses); iv (intravenous); ip (intraperitoneal); im (intra-

muscular); sc (subcutaneous); po (peroral); m.p. (melting

point); sp.g. (specific gravity).

Drugs and chemicals: The following abbreviations may

be used without definition: NAD�, NADH, NADP�,NADPH, FMN, FAD, ATP et al., RNA, DNA, UDP-

glucuronic acid, Tris, EDTA; SKF 525-A; all other abbre-

viations should be explained in a single footnote at the

point ofuse ofthe first one. Cytochromes should be named

as follows: cytochrome b5, cytochrome c, cytochrome P-

450. Generic names of drugs should be used; the trade-

name, capitalized, may be given in parentheses after the

first use of the generic name. Where no generic name

exists, a code number may be used, but the full chemical

name of the compound must be given in parentheses

following the first use of the number. Trade-names and

code numbers should not be used in the title.

The composite character of drugs which are mixtures

of stereoisomers must be brought to the attention of the

reader. The prefix rac-, e.g. rac-propranolol, in the case of

racemates, and (Z/E)- or cis/trans- in the case ofthat typeof isomer is obligatory. The implications of the composite

nature of the drugs studies for the interpretation of the

data measured and the conclusions drawn must be made

explicit.

Page charges: authors are assessed page charges at the

rate of$30 per printed page. With the galley proof, authors

will receive a request for page charges. These charges will

be assessed unless they involve personal financial hard-

ships to the authors. Payment of the charge is not a

condition for publication. Neither the editors nor review-

ers know who has paid the charge.

DRUG METABOLISM AND DISPOSITION

Vincent G. Zannoni, Editor

Robert L. Susick, Jr., Associate EditorMichele Kranick and Tern Kisner, Assistants to the Editor

Editorial Advisory Board

Alvito P. Alvares Charles T. Gombar Gary PollackGhulan A. S. Ansari David W. Hem Russell A. Prough

John R. Bend Aziz Karim Louis RadulovicJudy L. Bolton Dennis R. Koop Lora E. RikansMichael J. Brabec Arun P. Kulkarni Paul H. SatoJoanne Brodfuehrer Bert N. La Du William H. SchaeferJohn Caldwell Serrine S. Lau Don W. ShoemanArthur K. Cho Gerald A. LeBlanc Robert C. SmartAlan B. Combs Walter G. Levine Philip C. SmithC. Edgar Cook Fedor Medzihradsky Elliot S. VesellEdward Domino Joseph N. Miceli Mary Vore

Kenneth H. Dudley Terrence J. Monks William J. WaddellDeanne M. Dulik Hasan Mukhtar Thomas WalleHarry W. Eckerson Catherine M. Neumann

Board of Publications Trustees

Kenneth E. Moore, Chairman Marlene L. Cohen Marcus M. ReidenbergArthur J. Atkinson, Jr. T. Kendall Harden Robert E. StitzelWilliam A. Cattenall John A. Harvey Vincent G. Zannoni

Horace Loh

Executive Officer

Kay A. Croker

VOLUME 20

1992

Copyright © 1992 by The American Society for Pharmacologyand Experimental Therapeutics